Effective tailoring of cefepime into bilosomes: A promising nanoplatform for enhancing oral absorption, extending half-life, and evaluating biocompatibility, antibacterial, anti-biofilm, anti-breast cancer activity, ex-vivo, and in-vivo studies.

The clinical implication of cefepime HCl (CEF) is compromised owing to restricted oral bioavailability and harmful adverse effects without any authorized oral formulation available. The present investigation provides an innovative sustained-release oral drug delivery strategy that tackles the challenges of limited oral bioavailability and prolongs the half-life of CEF. Accordingly, CEF was loaded into a bilosome, a liposome or noisome-based vesicle employing bile salt as a permeation enhancer.

Clarithromycin-tailored cubosome: A sustained release oral nano platform for evaluating antibacterial, anti-biofilm, anti-inflammatory, anti-liver cancer, biocompatibility, ex-vivo and in-vivo studies.

The clinical implication of clarithromycin (CLT) is compromised owing to its poor solubility and, subsequently, bioavailability, unpalatable taste, rapid metabolism, short half-life, frequent dosing, and adverse effects. The present investigation provides an innovative sustained-release oral drug delivery strategy that tackles these challenges. Accordingly, CLT was loaded into a cubosome, a vesicular system with a bicontinuous cubic structure that promotes solubility and bioavailability, provides a sustained release system combating short half-life and adverse effects, masks unpleasant taste, and protects the drug from destruction in gastrointestinal tract (GIT).